For questions about financial assistance, call 1-866-MY-APL-ASSIST
Your game plan. Our support.
The ApellisAssist® support team will work with you to identify the right programs for affordable access to treatment.
Jonathan, a real person who's taken EMPAVELI
ApellisAssist has you covered. There are multiple programs to provide eligible patients with financial assistance and offer benefits investigation support.
The Apellis Copay Program can help eligible patients with commercial insurance lower their copay costs for EMPAVELI.*,†
With our Copay Program eligible patients may pay as little as $0 for EMPAVELI.‡
The Apellis Bridge Program can help with interruptions or changes in insurance. If your insurance provider or your plan has changed, you may experience an interruption in coverage. If this occurs, you could be eligible for a temporary supply of EMPAVELI through the Apellis Bridge Program.§
If you don’t have insurance or your insurance only provides limited coverage, the Apellis Patient Assistance Program may be able to help you obtain EMPAVELI at no cost.§
ApellisAssist helps you access EMPAVELI and explore affordability options. Call the ApellisAssist team at 1-866-MY-APL-ASSIST (1-866-692-7527) from 8 AM-8 PM ET, Monday-Friday. ApellisAssist can also connect you to a pharmacist who is available 24 hours a day.
*The Apellis Copay Program is for eligible patients who are enrolled in the ApellisAssist program, are commercially insured, and who are not covered under government insurance programs such as Medicaid, Medicare, CHIP, VA/DoD, or TRICARE.
†Additional terms and conditions apply. Program terms are subject to change.
‡Terms and Conditions apply. Program terms subject to change. Subject to annual benefit limit.
§Terms and conditions apply. Program terms are subject to change.
With EMPAVELI, you’re not alone. When you enroll in ApellisAssist, you’ll get dedicated support every step of the way.
Your ACE is there for you from the start. They are trained professionals with nursing backgrounds who offer:
“I’m here to make sure every person I
support feels confident and comfortable
with administering their EMPAVELI
treatment. ”
—Kristen, a real ACE
Individual experiences may vary.
Talk to your doctor about whether
EMPAVELI is right for you.
Through ApellisAssist, a Care Coordinator will:
Care Coordinators and ACEs do not give medical advice. Talk to your doctor for treatment-related questions.
Insurance questions? In need of financial assistance?
Call an ApellisAssist representative at 1-866-MY-APL-ASSIST (1-866-692-7527) to connect with your Care Coordinator about insurance questions or financial assistance programs that are available for eligible patients.
Our ApellisAssist team offers support to help you obtain any vaccinations recommended before starting EMPAVELI.
Because EMPAVELI affects part of the immune system, certain vaccines are required to help protect you against serious infections.
The Vaccine Coordinator through a speciality pharmacy will help by:
The Vaccine Coordinator through a speciality pharmacy will help by:
The FDA requires the REMS (Risk Evaluation and Mitigation Strategy) to ensure your safety when using EMPAVELI.
C3G=C3 glomerulopathy; DoD=Department of Defense; IC-MPGN=immune-complex membranoproliferative glomerulonephritis; VA=United States Department of Veterans Affairs.
EMPAVELI is a medicine that affects your immune system and may lower the ability of your immune system to fight infections.
EMPAVELI increases your chance of getting serious infections caused by encapsulated bacteria such as Streptococcus pneumoniae, Neisseria meningitidis, and Haemophilus influenzae type B. These serious infections may quickly become life-threatening or cause death if not recognized and treated early.
Your healthcare provider will give you a Patient Safety Card about the risk of serious infections. Carry it with you at all times during treatment and for 2 months after your last EMPAVELI dose. Your risk of serious infections may continue for several weeks after your last dose of EMPAVELI. It is important to show this card to any healthcare provider who treats you. This will help them diagnose and treat you quickly.
EMPAVELI is only available through a program called the EMPAVELI Risk Evaluation and Mitigation Strategy (REMS). Before you can take EMPAVELI, your healthcare provider must enroll in the EMPAVELI REMS program, counsel you about the risk of serious infections caused by certain bacteria, give you information about the symptoms of serious infections, make sure that you are vaccinated against serious infections caused by encapsulated bacteria and that you receive antibiotics if you need to start EMPAVELI right away and you are not up to date on your vaccines, and give you a Patient Safety Card about your risk of serious infections.
Do not take EMPAVELI if you:
Before you take EMPAVELI, tell your healthcare provider about all of your medical conditions, including if you:
Tell your healthcare provider about all the vaccines you receive and medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements which could affect your treatment.
EMPAVELI can cause serious side effects including allergic reactions. Allergic reactions can happen during your EMPAVELI infusion and can be life-threatening. Stop your EMPAVELI infusion and get emergency medical care right away if you get any of these symptoms during your EMPAVELI infusion:
The most common side effects in adults and children 12 years of age and older with C3G or primary IC-MPGN treated with EMPAVELI include injection-site reactions, fever, common cold, flu, cough, and nausea.
These are not all of the possible side effects of EMPAVELI. Tell your healthcare provider about any side effect that bothers you or that does not go away.
Call your healthcare provider for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
EMPAVELI is a prescription medicine used to treat adults and children 12 years of age and older with a kidney disease called complement 3 glomerulopathy (C3G) or primary immune-complex membranoproliferative glomerulonephritis (IC-MPGN), to reduce levels of protein in the urine (proteinuria).
Please see full Prescribing Information, including Boxed WARNING regarding risk of serious infections, and Medication Guide for additional information.
For questions about financial assistance, call 1-866-MY-APL-ASSIST
Sign up to join the community making bold moves in C3G and primary IC-MPGN:
Stay a move ahead.
By submitting this form, I acknowledge that I have reviewed, understood, and agree to the below guidelines, that I am at least 18 years of age and am legally competent to enter into this agreement, that I own all rights to the content submitted, and that I have received permission to submit the content from any other individual appearing in my submission for use by Apellis Pharmaceuticals, Inc. (“Apellis”), as set forth below.
Apellis can take, collect and use any content I have submitted to this webpage, including my photographs, film or recordings taken of my image and voice, my quotation or testimonial, as well as any personal health information contained in such photographs, film or recordings or provided on this submission form (collectively, “My Content and Information”). Apellis reserves the right to not post or use My Content and Information.
Apellis and its subsidiaries, affiliates, licensees, successors, assignees and those acting with its authority, have the right to use, re-use, broadcast, display and publish My Content and Information on social media, websites, displays, and emails. I waive all rights that I may have to claims for payment or royalties in connection with the posting or other usage of My Content and Information on these platforms. Apellis will contact me by e-mail or phone if it would like to feature My Content and Information elsewhere.
Any content that I submit to Apellis may be edited or excerpted in Apellis’ sole discretion to align with promotional requirements and the intended use of this site. I waive all rights in My Content and Information, including any right to inspect or approve My Content and Information prior to use or dissemination by Apellis. If significant changes are required, Apellis may contact me via e-mail or phone. Apellis will not use my e-mail address or phone number for any other purpose, unless I have separately opted into receiving communications from Apellis.
Adverse Events (“AEs”): Apellis will address any adverse events or side effects mentioned within submissions according to FDA regulations.
You may report side effects to FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
EMPAVELI is a medicine that affects your immune system and may lower the ability of your immune system to fight infections.
EMPAVELI increases your chance of getting serious infections caused by encapsulated bacteria such as Streptococcus pneumoniae, Neisseria meningitidis, and Haemophilus influenzae type B. These serious infections may quickly become life-threatening or cause death if not recognized and treated early.
Your healthcare provider will give you a Patient Safety Card about the risk of serious infections. Carry it with you at all times during treatment and for 2 months after your last EMPAVELI dose. Your risk of serious infections may continue for several weeks after your last dose of EMPAVELI. It is important to show this card to any healthcare provider who treats you. This will help them diagnose and treat you quickly.
EMPAVELI is only available through a program called the EMPAVELI Risk Evaluation and Mitigation Strategy (REMS). Before you can take EMPAVELI, your healthcare provider must enroll in the EMPAVELI REMS program, counsel you about the risk of serious infections caused by certain bacteria, give you information about the symptoms of serious infections, make sure that you are vaccinated against serious infections caused by encapsulated bacteria and that you receive antibiotics if you need to start EMPAVELI right away and you are not up to date on your vaccines, and give you a Patient Safety Card about your risk of serious infections.
Do not take EMPAVELI if you:
Before you take EMPAVELI, tell your healthcare provider about all of your medical conditions, including if you:
Tell your healthcare provider about all the vaccines you receive and medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements which could affect your treatment.
EMPAVELI can cause serious side effects including allergic reactions. Allergic reactions can happen during your EMPAVELI infusion and can be life-threatening. Stop your EMPAVELI infusion and get emergency medical care right away if you get any of these symptoms during your EMPAVELI infusion:
The most common side effects in adults and children 12 years of age and older with C3G or primary IC-MPGN treated with EMPAVELI include injection-site reactions, fever, common cold, flu, cough, and nausea.
These are not all of the possible side effects of EMPAVELI. Tell your healthcare provider about any side effect that bothers you or that does not go away.
Call your healthcare provider for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
EMPAVELI is a prescription medicine used to treat adults and children 12 years of age and older with a kidney disease called complement 3 glomerulopathy (C3G) or primary immune-complex membranoproliferative glomerulonephritis (IC-MPGN), to reduce levels of protein in the urine (proteinuria).
Please see full Prescribing Information, including Boxed WARNING regarding risk of serious infections, and Medication Guide for additional information.